Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $20 to $18.
April 26, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mizuho analyst Uy Ear maintains a Neutral rating on Sage Therapeutics and lowers the price target from $20 to $18.
The reduction in price target by Mizuho suggests a less optimistic outlook on Sage Therapeutics' stock performance in the short term, potentially leading to a negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100